PDGFRA and glioblastoma: In contrast, PDGFRA amplification and/or mutation was a significant indicator of poor prognosis, as determined by our univariate (HR: 2.11 [1.03–4.31], P = .041) and multivariate (HR: 2.26 [1.04–4.91], P = .039) analyses in TERTp-mutant GBM (Supplementary Table 1).